Focus Stocks
Investor Notice: The Rosen Law Firm Announces Investigation of Shareholder Securities Claims Against AspenBio Pharma, Inc. --- APPY
Published on Friday, 03 September 2010 20:05 Written by TradersHuddle Staff
NEW YORK-( Business Wire )-The Rosen Law Firm today announced that it has commenced an investigation into allegations that AspenBio Pharma, Inc. (“AspenBio” or the “Company”) (Nasdaq: APPY - News) violated the federal securities laws by issuing false and misleading statements to investors about its product candidate AppyScore.
Since as early February 15, 2006, AspenBio has been touting AppyScore as an effective test to diagnose appendicitis. On June 7, 2010, the Company disclosed there was “unexplained variability” in the test results of its most recent clinical trial for AppyScore. Then, on July 19, 2010, the Company disclosed more details showing that the AppyScore was not effective at detecting appendicitis because, among other things, the test could not differentiate between appendicitis and other medical conditions. This adverse news caused the Company’s stock to drop substantially and investors have suffered significant losses.
As a result of these allegations, the Rosen Law Firm is preparing a class action lawsuit on behalf of investors who suffered losses purchasing AspenBio stock.
You may access the website at http://www.rosenlegal.com to participate in the proposed class action.
If you purchased AspenBio securities and would like further information concerning your legal rights or your ability to recover your investment losses, please contact Laurence Rosen, Esq. or Phillip Kim, Esq. toll-free at 866-767-3653 or email This e-mail address is being protected from spambots. You need JavaScript enabled to view it. or This e-mail address is being protected from spambots. You need JavaScript enabled to view it. or visit the website at www.rosenlegal.com
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Related Articles
Related Partner Headlines
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
A Look At A New Small-Cap ETF - Benzinga -
Santorum Sprints Ahead of the Field - TheStreet.com -
ETFs to Watch February 8, 2012 - Benzinga -
Benzinga's Microcap Movers for Tuesday February 7, 2012 - Benzinga -
'Fast Money' Recap: Disney Deserves to Go Higher - TheStreet.com -
Dan Nathan's Apple Inc. Trade - Benzinga -
Market Preview: Are Banks Overbought? - TheStreet.com -
Fast Money Picks For February 8th - Benzinga
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,878.20 Trade time:4:05PM EST Value change:▲33.07 (0.26%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,347.05 Trade time:4:32PM EST Value change:▲2.72 (0.20%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,904.08 Trade time:5:16PM EST Value change:▲2.09 (0.07%)In The Wires
-
Valmont Industries, Inc. Fourth Quarter 2011 Earnings Conference Call -
Doritos "Sling Baby" Wins 2012 USA TODAY Facebook Super Bowl Ad Meter -
Radio One, Inc. Reports Q4 2011 Preliminary Revenue Information, Q1 2012 Pacings Update and Announces Date of its Year End 2011 Earnings Call -
Vista Gold Corp. Announces Transaction with Invecture Group to Advance the Concordia Gold Project in Mexico -
IIJ Announces Nine Months Financial Results for the Fiscal Year Ending March 31, 2012 -
AsiaInfo-Linkage, Inc. Special Committee Selects Financial Advisor -
Notice From the Securities Arbitration Law Firm of Klayman & Toskes to Merrill Lynch Customers Who Purchased Biltmore CDO 2007-1 -
Notice From the Securities Arbitration Law Firm of Klayman & Toskes to Merrill Lynch Customers Who Purchased Bernoulli High Grade CDO-II






